Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC-PEG Asparaginase vs Oncaspar in Children and Adolescents With ALL or Lymphoblastic Lymphoma
NCT01574274Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2012
- Primary completion
- Jul 2021
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of calaspargase pegol in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), sponsored by Dana-Farber Cancer Institute. Started Jun 2012; status: active, not recruiting.
02
Drugs
calaspargase pegol
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT01574274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01574274.